Current Atherosclerosis Reports

, 16:408

Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors

  • Alison Cameron-Vendrig
  • Dhanwantee Mundil
  • Mansoor Husain
Vascular Biology (RS Rosenson, Section Editor)

DOI: 10.1007/s11883-014-0408-2

Cite this article as:
Cameron-Vendrig, A., Mundil, D. & Husain, M. Curr Atheroscler Rep (2014) 16: 408. doi:10.1007/s11883-014-0408-2
Part of the following topical collections:
  1. Topical Collection on Vascular Biology

Abstract

Atherothrombotic cardiovascular events are a leading cause of morbidity and mortality in patients with type 2 diabetes (T2D). A number of factors beyond hyperglycemia contribute to this increased risk of cardiovascular events in T2D, including elevated blood pressure, dyslipidemia, inflammation, endothelial dysfunction, and enhanced platelet activation. Importantly, most currently available antihyperglycemic treatments for T2D do not address these additional mechanisms. Indeed, we posit that this may explain why more intensive treatment of hyperglycemia has not contributed to a reduced incidence of cardiovascular events in subjects with T2D. Incretin-targeted therapies, such as dipeptidyl peptidase 4 inhibitors, are a relatively new class of antidiabetic treatments, and preclinical as well as small mechanistic clinical studies suggest that they exert beneficial cardiovascular effects. This review focuses specifically on the potential antiatherothrombotic effects of dipeptidyl peptidase 4 inhibitors.

Keywords

IncretinDipeptidyl peptidase 4Glucagon-like peptide 1CardiovascularHeart failureAtherothrombosisAtherosclerosisThrombotic eventMyocardial infarctionStroke

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Alison Cameron-Vendrig
    • 1
    • 2
  • Dhanwantee Mundil
    • 1
    • 3
  • Mansoor Husain
    • 1
    • 3
    • 4
  1. 1.Toronto General Research InstituteTorontoCanada
  2. 2.Li Ka Shing Knowledge Institute of St Michael’s HospitalTorontoCanada
  3. 3.Department of PhysiologyUniversity of TorontoTorontoCanada
  4. 4.Department of Medicine and Heart and Stroke Richard Lewar Centre of ExcellenceTorontoCanada